Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Femasys ( (FEMY) ) just unveiled an update.
Femasys Inc. amended its November 3, 2025 Securities Purchase Agreement with certain lenders on March 19, 2026, removing the share combination event adjustment from its senior secured convertible notes and associated warrants effective December 31, 2025. In exchange, the company is issuing 16,378,563 unregistered Series D-1 warrants, each exercisable at $0.58 and mirroring the share count of the lenders’ existing Series A-1 warrants, in a private placement to accredited investors under a registration exemption.
Separately, on March 17, 2026, director Joshua Silverman resigned from Femasys’ board, with the company stating his departure did not stem from any disagreement regarding operations or policies. On March 18, 2026, the board appointed anesthesiologist and healthcare technology specialist Kenneth D. Eichenbaum, M.D., as an independent Class II director under a nomination right held by lead lender Pointillist Partners, enhancing lender representation and clinical expertise on the board ahead of the 2026 annual meeting.
The most recent analyst rating on (FEMY) stock is a Buy with a $1.50 price target. To see the full list of analyst forecasts on Femasys stock, see the FEMY Stock Forecast page.
Spark’s Take on FEMY Stock
According to Spark, TipRanks’ AI Analyst, FEMY is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses and negative cash flow). Technicals remain soft-to-neutral with a negative MACD and price below key longer-term averages. Corporate events are mixed—FDA and commercialization progress are positives, but listing-compliance risk offsets much of that support.
To see Spark’s full report on FEMY stock, click here.
More about Femasys
Femasys Inc., a Nasdaq-listed medical technology company, focuses on women’s health through minimally invasive reproductive and gynecological solutions. The company targets unmet needs in fertility and permanent birth control, positioning itself within the broader healthcare and medtech markets serving both patients and physicians.
Average Trading Volume: 865,217
Technical Sentiment Signal: Sell
Current Market Cap: $34.43M
For detailed information about FEMY stock, go to TipRanks’ Stock Analysis page.